Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril.

Proc Natl Acad Sci U S A

Laboratorium für Physikalische Chemie, Eidgenössische Technische Hochschule Zürich, 8093 Zurich, Switzerland;

Published: August 2016

Amyloid-β (Aβ) is present in humans as a 39- to 42-amino acid residue metabolic product of the amyloid precursor protein. Although the two predominant forms, Aβ(1-40) and Aβ(1-42), differ in only two residues, they display different biophysical, biological, and clinical behavior. Aβ(1-42) is the more neurotoxic species, aggregates much faster, and dominates in senile plaque of Alzheimer's disease (AD) patients. Although small Aβ oligomers are believed to be the neurotoxic species, Aβ amyloid fibrils are, because of their presence in plaques, a pathological hallmark of AD and appear to play an important role in disease progression through cell-to-cell transmissibility. Here, we solved the 3D structure of a disease-relevant Aβ(1-42) fibril polymorph, combining data from solid-state NMR spectroscopy and mass-per-length measurements from EM. The 3D structure is composed of two molecules per fibril layer, with residues 15-42 forming a double-horseshoe-like cross-β-sheet entity with maximally buried hydrophobic side chains. Residues 1-14 are partially ordered and in a β-strand conformation, but do not display unambiguous distance restraints to the remainder of the core structure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003276PMC
http://dx.doi.org/10.1073/pnas.1600749113DOI Listing

Publication Analysis

Top Keywords

structure disease-relevant
8
disease-relevant aβ1-42
8
neurotoxic species
8
atomic-resolution structure
4
aβ1-42
4
aβ1-42 amyloid
4
amyloid fibril
4
fibril amyloid-β
4
amyloid-β aβ
4
aβ humans
4

Similar Publications

Peptide therapeutics, a major class of medicines, have achieved remarkable success across diseases such as diabetes and cancer, with landmark examples such as GLP-1 receptor agonists revolutionizing the treatment of type-2 diabetes and obesity. Despite their success, designing peptides that satisfy multiple conflicting objectives, such as target binding affinity, solubility, and membrane permeability, remains a major challenge. Classical drug development and structure-based design are ineffective for such tasks, as they fail to optimize global functional properties critical for therapeutic efficacy.

View Article and Find Full Text PDF

Neuromorphic-enabled video-activated cell sorting.

Nat Commun

December 2024

State Key Laboratory of Precision Measurement Technology and Instrument, Department of Precision Instrument, Tsinghua University, Beijing, China.

Imaging flow cytometry allows image-activated cell sorting (IACS) with enhanced feature dimensions in cellular morphology, structure, and composition. However, existing IACS frameworks suffer from the challenges of 3D information loss and processing latency dilemma in real-time sorting operation. Herein, we establish a neuromorphic-enabled video-activated cell sorter (NEVACS) framework, designed to achieve high-dimensional spatiotemporal characterization content alongside high-throughput sorting of particles in wide field of view.

View Article and Find Full Text PDF
Article Synopsis
  • Tau is a protein that helps maintain the structure and function of neurons, but it misfolds in diseases like Alzheimer's, leading to neuronal damage.
  • Soluble tau oligomers, which are toxic to neurons, disrupt synaptic function and contribute to disease progression, making them important targets for study.
  • Traditional detection methods struggle with sensitivity for small tau aggregates, but advanced techniques like smFRET and SiMPull provide better insights, aiding in earlier detection and potential therapy development for tau-related diseases.
View Article and Find Full Text PDF

Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck in the development of targeted therapeutics. Here, we introduce targeted recognition of antigen-MHC complex reporter for MHC I (TRACeR-I), a generalizable platform for targeting peptides on polymorphic HLA-A*, HLA-B* and HLA-C* allotypes while overcoming the cross-reactivity challenges of TCRs. Our TRACeR-MHC I co-crystal structure reveals a unique antigen recognition mechanism, with TRACeR forming extensive contacts across the entire peptide length to confer single-residue specificity at the accessible positions.

View Article and Find Full Text PDF

Neuropsychiatric conditions pose substantial challenges for therapeutic development due to their complex and poorly understood underlying mechanisms. High-throughput, unbiased phenotypic assays present a promising path for advancing therapeutic discovery, especially within disease-relevant neural tissues. Here, we introduce NeuroPainting, a novel adaptation of the Cell Painting assay, optimized for high-dimensional morphological phenotyping of neural cell types, including neurons, neuronal progenitor cells, and astrocytes derived from human stem cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!